NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free LENZ Stock Alerts $15.72 +0.27 (+1.75%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$15.05▼$16.0050-Day Range N/A52-Week Range$14.07▼$29.82Volume200,720 shsAverage Volume96,332 shsMarket Capitalization$57.36 millionP/E RatioN/ADividend YieldN/APrice Target$31.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get LENZ Therapeutics alerts: Email Address LENZ Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside99.3% Upside$31.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$15 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 starsMedical Sector227th out of 914 stocksBiological Products, Except Diagnostic Industry24th out of 153 stocks 4.5 Analyst's Opinion Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for LENZ. Previous Next 0.0 Dividend Strength Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LENZ. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for LENZ Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows6 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,000,075.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About LENZ Therapeutics Stock (NASDAQ:LENZ)LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More LENZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LENZ Stock News HeadlinesApril 21, 2024 | americanbankingnews.comCritical Survey: LENZ Therapeutics (LENZ) and Its CompetitorsApril 18, 2024 | morningstar.comLENZ Therapeutics IncApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 18, 2024 | americanbankingnews.comLENZ Therapeutics (NASDAQ:LENZ) Earns Outperform Rating from Leerink PartnrsApril 18, 2024 | americanbankingnews.comLENZ Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, William Blair Forecasts (NASDAQ:LENZ)April 18, 2024 | americanbankingnews.comQ1 2024 Earnings Forecast for LENZ Therapeutics, Inc. (NASDAQ:LENZ) Issued By Leerink PartnrsApril 14, 2024 | morningstar.comLENZ Therapeutics Inc LENZApril 10, 2024 | nasdaq.comLENZ Therapeutics, Inc. Common Stock (LENZ)April 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 10, 2024 | markets.businessinsider.comBlindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst SaysApril 3, 2024 | reuters.comLenz Therapeutics' eye disease drugs meet main goal of late-stage studyApril 3, 2024 | businesswire.comLENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsApril 2, 2024 | businesswire.comLENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia TrialsMarch 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOSee More Headlines Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$31.33 High Stock Price Target$34.00 Low Stock Price Target$28.00 Potential Upside/Downside+99.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($15.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.12% Return on Assets-27.96% Debt Debt-to-Equity RatioN/A Current Ratio39.20 Quick Ratio39.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$22.06 per share Price / Book0.71Miscellaneous Outstanding Shares3,649,000Free Float2,248,000Market Cap$57.36 million OptionableN/A Beta0.20 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Evert B. Schimmelpennink (Age 52)President, CEO, CFO, Secretary & Director Mr. James W. McCollumCo-Founder & DirectorMr. Gerald HornSenior Scientific Advisor & FounderMr. Domenick PorfidiaVice President of SalesMr. David MurphySenior Director of Marketing & Alliance DevelopmentMr. Shawn OlssonChief Commercial OfficerMr. Marc G. Odrich M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsEntera BioNASDAQ:ENTXJATT AcquisitionNYSE:JATTAligos TherapeuticsNASDAQ:ALGSTurnstone BiologicsNASDAQ:TSBXCidara TherapeuticsNASDAQ:CDTXView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 63,916 shares on 4/25/2024Ownership: 1.751%Ra Capital Management, L.P.Bought 998,009 shares on 3/21/2024Total: $15.00 M ($15.03/share)View All Insider TransactionsView All Institutional Transactions LENZ Stock Analysis - Frequently Asked Questions Should I buy or sell LENZ Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LENZ Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LENZ shares. View LENZ analyst ratings or view top-rated stocks. What is LENZ Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued twelve-month price objectives for LENZ Therapeutics' shares. Their LENZ share price targets range from $28.00 to $34.00. On average, they expect the company's share price to reach $31.33 in the next year. This suggests a possible upside of 99.3% from the stock's current price. View analysts price targets for LENZ or view top-rated stocks among Wall Street analysts. How have LENZ shares performed in 2024? LENZ Therapeutics' stock was trading at $16.20 at the beginning of the year. Since then, LENZ stock has decreased by 3.0% and is now trading at $15.72. View the best growth stocks for 2024 here. When is LENZ Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LENZ earnings forecast. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (1.75%). View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LENZ) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressProtect Your Bank Account Before It’s Too LateWeiss RatingsJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
